EUVIMEDEUVIMED entdecken
Open Access

Molecular determinants of ligand efficacy and potency in GPCR signaling

Franziska M Heydenreich iD, Maria Marti-Solano iD, Manbir Sandhu iD, Brian K Kobilka iD, Michel Bouvier iD, M Madan Babu iD

Science · 22.12.2023 · 382 (6677)

DOI: 10.1126/science.adh1859 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, erschienen am 22.12.2023. Verfasst von Franziska M Heydenreich und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA. Hauptthemen laut MEDLINE: Adrenergic beta-2 Receptor Agonists, Receptors, Adrenergic, beta-2. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, Medical Research Council, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heterotrimeric guanine nucleotide–binding protein (G protein)–coupled receptors (GPCRs) bind to extracellular ligands and drugs and modulate intracellular responses through conformational changes. Despite their importance as drug targets, the molecular origins of pharmacological properties such as efficacy (maximum signaling response) and potency (the ligand concentration at half-maximal response) remain poorly understood for any ligand-receptor-signaling system. We used the prototypical adrenaline–β2 adrenergic receptor–G protein system to reveal how specific receptor residues decode and translate the information encoded in a ligand to mediate a signaling response. We present a data science framework to integrate pharmacological and structural data to uncover structural changes and allosteric networks relevant for ligand pharmacology. These methods can be tailored to study any ligand-receptor-signaling system, and the principles open possibilities for designing orthosteric and allosteric compounds with defined signaling properties.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic beta-2 Receptor AgonistsReceptors, Adrenergic, beta-2HumansAllosteric RegulationBiosensing TechniquesLigandsProtein ConformationSignal TransductionBioluminescence Resonance Energy Transfer Techniques

Substanzen

Adrenergic beta-2 Receptor AgonistsLigandsReceptors, Adrenergic, beta-2

Autor:innen und Institutionen

  • Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
  • MRC Laboratory of Molecular Biology, Cambridge, UK.
  • Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.
  • Department of Pharmacology, University of Cambridge, Cambridge, UK.
  • Department of Structural Biology and Center of Excellence for Data-Driven Discovery, St. Jude Children's Research Hospital, Memphis, TN, USA.

ORCID-Profile: Franziska M Heydenreich, Maria Marti-Solano, Manbir Sandhu, Brian K Kobilka, Michel Bouvier, M Madan Babu

Förderung

  • Wellcome Trust
  • Medical Research Council
  • NINDS NIH HHS

Zitieren

APA

Heydenreich, F. M., Marti-Solano, M., Sandhu, M., Kobilka, B. K., Bouvier, M., & Babu, M. M. (2023). Molecular determinants of ligand efficacy and potency in GPCR signaling. Science, 382(6677). https://doi.org/10.1126/science.adh1859

Vancouver

Heydenreich FM, Marti-Solano M, Sandhu M, Kobilka BK, Bouvier M, Babu MM. Molecular determinants of ligand efficacy and potency in GPCR signaling. Science. 2023;382(6677). doi:10.1126/science.adh1859

BibTeX
@article{Heydenreich2023,
  author = {Heydenreich, Franziska M and Marti-Solano, Maria and Sandhu, Manbir and Kobilka, Brian K and Bouvier, Michel and Babu, M Madan},
  title = {Molecular determinants of ligand efficacy and potency in GPCR signaling},
  journal = {Science},
  year = {2023},
  volume = {382},
  number = {6677},
  doi = {10.1126/science.adh1859}
}
Kostenlos starten →